text:
Patriot Games
November 8, 2012 § 6 Comments
I was talking with my good friend and colleague Steven Cook about the news that Turkey was planning to request that NATO deploy Patriot missiles along the Syrian border, and since we both had nearly identical thoughts on the subject, we thought we'd link O&Z and From the Potomac to the Euphrates together and write a joint post. You can read it here or on Steven's blog (where he has a cool picture of a Patriot missile battery up top).
Wednesday saw a strange confluence of events surrounding Turkey and its oft-stated determination to intervene in Syria with the help of its Western allies. It began with an unnamed Turkish Foreign Ministry official – presumably Foreign Minister Ahmet Davutoğlu – revealing that there have been talks between Turkey and the United States about deploying Patriot missile batteries on the Syrian border. According to this report, the purpose of the Patriots would be to create a safe zone inside of Syria as a way of supporting a limited no-fly zone. This report would have been unusual by itself given that Patriot missiles are an odd vehicle to use for creating a no-fly zone, but it was particularly puzzling given Prime Minister Erdoğan's statement the day before explicitly disavowing any Turkish intentions to buy Patriot missiles. More drama ensued after Davutoğlu was identified as the official claiming that a NATO deployment of Patriots was imminent, with the Foreign Ministry subsequently denying that Davutoğlu had ever made such a claim.
There are a couple of things here that don't quite seem right. First, Patriot missiles are not what one would typically use to enforce or support a no-fly zone. Patriots are defensive weapons, designed to shoot down incoming missiles and not fix-winged aircraft or helicopters. Their deployment would only make sense if Ankara were concerned about a barrage of Syria's Scud missiles tipped with chemical weapons—a largely theoretical threat. Second, despite the calls for intervention in Syria from some quarters of Washington, the Obama administration has been reluctant to get involved in Syria beyond technical support that may or may not include small arms. Anonymous reports coming out of Turkey the day after the election claiming that the U.S. and NATO are now about to prepare for staging a no-fly zone seem a little more than idle chatter. Neither the White House nor the State Department nor the Pentagon have demonstrated any appetite for getting involved in Syria, with its layers of political, sectarian, and regional complexities that could suck Washington into yet another long-term military and diplomatic commitment in the Muslim world. Against this backdrop, the recent meeting that the United States orchestrated in Doha to broaden the Syrian opposition was an effort to preclude a greater American involvement in Syria's civil war.
The deployment of the Patriots is likely a precursor to no new initiative, but rather has more to do with U.S. and NATO relations with Turkey. Ankara, incapable of managing the Syrian crisis on its own, has continually sought to involve Western powers in a greater way. For much of the past year, Prime Minister Erdoğan has been attempting to drum up support for outside intervention by threatening to unilaterally create a buffer zone inside Syria, making noise about invoking NATO Article 5, calling out the U.S. for dragging its feet while Assad butchers his own people, and implying that NATO is in danger of losing its credibility as the Syrian civil war drags on. Despite a combination of public and private cajoling, Erdoğan has made little headway, and Wednesday's barrage of leaks and half-truths fits into the pattern of doing anything possible to pull the U.S. into Syria one way or another. By making it seem as if a no-fly zone is a fait accompli, Ankara is hoping to create enough momentum to spur some real action. Yet rather than respond to the Turkish government's posturing and efforts to shame the United States and NATO into taking Turkey's preferred course, Ankara's allies have sought to placate it with a symbolic dispatch of largely useless weapons.
Overall, the announcement that Patriots will be deployed to Turkey fits a pattern that has developed in Turkey's relations with its traditional partners, who have sought to keep Ankara minimally satisfied without actually having to commit much of anything to Syria. If scattering Patriot missile batteries along the Turkish-Syrian border is the price of keeping Turkey temporarily happy, it's a pretty small price to pay, and certainly nothing compared to the cost of actually intervening in Syria.
§ 6 Responses to Patriot Games
Actually, militarily, deploying patriots to the border makes sense. Especially, given the unpredictable behavior of the Syrian leadership. A good offense is a strong defense after all. By having NATO deploy to the border, it forces NATO's hand should the Turks act unilaterally, even if the Turks decide limited operations (see incursions into Iraq for reference). The region can't afford anymore time, the radicals will set up shop the longer this drags on. And a failed state in the Middle East, with fertile soil for extremists in Syria, is the last thing the world needs, let alone the Obama administration.
[…] is to give Turkey a helping hand on Syria. Deploying Patriot missiles along the Syrian border is the U.S. and NATO response to keeping Turkey happy and by taking constant digs at the EU, Erdoğan is trying to coax some European action in order to […]
[…] to his conspiracy theorizing about Turkey being in cahoots with Israel, but the fact remains that providing Ankara with some peace of mind is worth the cost irrespective of whether the threat from Syria is real or not. While the Patriots […]
Who is that in the avatar?
Interesting. I presume a parallel would be that of a Gulf Arab migrating to the west and wearing western clothing. More interestingly is how Ben-Gurion's policies and thinking helped create and destroy, by implosion, modern Israel.
"No people always behaves according to logic, common sense, and best interests." Ben Gurion
Ben-Gurion and the Palestinian Arabs, From Peace to War (p188-189)
Shabtai Teveth


text: Want to look good this fall while still feeling warm and comfortable? Then throw on a pair of socks before stepping into your heels or flats. All the celebs are doing it! (Personally, we've been known to rock a pair of thigh-highs over tights or leggings, but we tend to lean more towards the "warm and comfortable" end of the spectrum.) Before the really cold weather hits, check out our gallery of all the different ways to wear your sock-n-shoe ensemble. More

subset: commoncrawl


text:
MANUFACTURER: Nikon
Review This Item
A huge ocular, generous field of view and maximum, 95% light transmission make the NIKON Monarch 3-12x42 SF Riflescope, Nikoplex Reticle, Matte Black (8419) the "must have" for any kind of big game hunting.
Nikon designed the Monarch around a new optical system created to give shooters increased versatility and superlative performance with virtually any type of rifle, in any caliber and in any imaginable hunting situation.
While still maintaining the American-preferred one-inch diameter main body tube, Nikon engineers developed the new Monarch series to not only provide the shooter with a big, bright, sharp sight picture, but at the same time minimize the overall length of the riflescope - and maximize the mount ring spacing capability.
The resulting line of riflescopes pushes the envelope of optical performance with Nikon's lead-and-arsenic-free Eco-Glass lenses and trademark Ultra ClearCoat anti-reflective multicoatings, is fast-handling, pleasing to the eye and very importantly, allows for mounting on virtually any rifle - even magnum-length actions.
The Monarch riflescope features the Ultra ClearCoat optical system, which provides the shooter with a bright, sharp, incredibly flat sight picture and light transmission up to its theoretical maximum - 95%.
In addition to the enhanced ring spacing, the new Monarch riflescope design includes the new Monarch Eye Box design with its impressive 4-time zoom range and a very comfortable four inches of eye relief that remains constant throughout the power range without sacrificing field of view. In contrast, most competitive riflescopes supply less than 3-times magnification zoom capability and eye relief that varies by as much as a full inch between high and low powers.
The Monarch's massive ocular lens also delivers both a large high-resolution sight picture and the maximum field of view corresponding to each power setting. As an additional convenience feature, Nikon has placed rear-facing magnification indicators on the zoom control and included a quick-focus eyepiece on the new Monarch Eye Box.
All Monarch riflescope models utilize Nikon's precise, repeatable, hand turn reticle adjustments and feature the company's new Interchangeable Turret Technology system, which allows shooters to switch out turret knobs and caps for maximum convenience and versatility. This riflescope offers 1/4-MOA adjustment and can be customized with accessory target-style windage and elevation adjustment knobs and caps.
This model with magnification exceeding 10-power also features a locking side focus knob on the left side of the adjustment turret. This ergonomically-positioned control allows for precise parallax adjustment maintenance at virtually any range from 50 yards to infinity.
The Monarch 3-12x42 SF riflescope is covered by Nikon's Lifetime Full Warranty.
Shipping Restrictions:Can't ship to .See more info here.
Due to the nature of this item, it may be restricted from shipment to the territories listed under Shipping Restrictions. It may require a permit or may be prohibited from ownership in these areas. Contact your local law enforcement/government officials to find out more. If you add it to the shopping cart and check out with it, it may be removed from your order by our customer service team (your credit card will not be charged for the item).
Contact for details.
Free shipping available
Shipping charges will be applied
No Sales Tax (except Texas)
Availability: Discontinued
Usually ships in one business day
Usually re-stocks in 1-2 weeks
For more detailed information on the process click HERE.
Subscribe to WEBYBLAST supersavings notification newsletter.
View sample newsletter. Click here (will open a new window)
We respect your privacy. Your personal info is never sold, shared or shown to anyone outside Webyworld. Never. Ever. Read our Privacy Policy Here Click here (will open a new window)


text:
Description & Highlights
Keurig Platinum Brewing System
Get your day off on the right foot with the Keurig Platinum Brewing System (B70B) brewing up a warming cup of coffee in minutes. This convenient home brewing system can quickly brew a single cup with your choice of patented Keurig K-Cups. Operation is a breeze thanks to its user-friendly interface letting you adjust temperature and brew size. Even maintenance is hassle-free with dishwasher-safe parts and a removable 60-ounce water reservoir.
Convenient:This home brewing system is designed to brew a single cup in mere minutes with the patented Keurig K-Cups.
Versatile:Its user-friendly interface makes brewing a breeze with adjustable temperature and 5 size options.
Easy:Dishwasher-safe parts and a removable 60-ounce water reservoir makes for hassle-free maintenance.
- Model: B70BKeurig Platinum Brewing System
- Brand: KeurigIncludes 12-count K-Cup variety pack and 12-count Newman's Own Organics K-Cups
- Single-cup home brewing system3 brew-size options
- For use with patented Keurig K-CupsRemovable drip tray
- One-touch control panelRemovable 60-ounce water reservoir
- Blue, backlit LCD displayDescale indicator
- Programmable On/OffDishwasher-safe parts
- Adjustable brew temperatureInput Voltage: 120 V / 60 Hz
- Water filter handle and replacement water filter cartridge includedWeight: 12 lbs
- Warranty: 1-Year LimitedDimensions: 13.0"H x 9.8"W x 13.3"D
- Height: 13"
- Width: 9.8"
- Depth: 13.3"


text:
"A still small voice spake unto me. Thou art so full of misery, Were it not better not to be?"
IS there any one among us, who, at some moments of their lives, has not heard that voice asking them this despairing question? Is there any one who, at some moment or other, has not been tempted to answer "Yes, far, far better!" Is there any one, whoever thinks at all, that has not had black minutes and hours—minutes and hours when he says blankly, hopelessly to himself, "There is no God: there can be no beneficent Deity to love us and take care of us, or he never would let us be so very, very desolately wretched." Sometimes we feel page: 143 that we must curse God and die; it would be such a relief to us; curse God, as Job's wife is supposed to have urged her much enduring lord to do, as a cure for his boils; that is, if she did not urge him to bless God and die, as the word has either signification: in which case the poor woman's character for piety has been shamefully taken away for the last three or four thousand years.
Sometimes we say to ourselves that surely some malevolent tricksy demon must have the world's government reins in his fiend hands—some demon that delights in thwarting our poor little plans, in inventing new and ingenious diseases to rack our poor patient bodies. Our very wishing anything seems to drive the object wished for farther away; our very dreading anything seems to draw the dreaded object magnetically nearer. In every newspaper we take up, we see "melancholy suicides," "horrible murders," "fatal accidents," "economic funeral companies;" and often we lay it down with a dull numb feeling that the page: 144 world is all out of joint; all discord and jangling dissonance.
I seemed now in my complete life‐hatred and bitterness to be prisoned in some narrow black valley—some deep gulley between great frowning granite peaks. I could not climb up their smooth slant sides, to see the sunrise washing the low morning clouds, and the gray morning billows with his flamy streams. I was groping with hands stretched out before me blindly, among the boulders and the pit‐falls, and the sullen black pools in the valley bottom; and I must stay groping page: 146 there as I felt, till the oil of my life's lamp were burned out, till I sat down and died there amid the darkness and the doleful beasts and the murky stagnant waters.
"If," thought I, "I had been an old roué of seventy, who had dedicated all my three score and ten years to the debasing of soul and body, I could hardly have incurred more woful penalties than my nineteen summers of insipid innocence had drawn upon my devoted head." Not even the consciousness of having made a sacrifice that raised me (at least in my own estimation) to a level with the Jewish maiden I have before alluded to; not even the consciousness of having been "high heroical" supported me much. I did not grudge the sacrifice I had made; if it had to be done over again, I should do it over again; but I thought myself entitled to make as many wry faces over it as I felt inclined, and their name was legion.
One day, Dolly entering, cat‐like, in her long, straight serge gown, found me page: 147 grovelling—lying all along on the floor, prone, while tears rushed in rivers from my foolish blue eyes, and laid the dust on the carpet.
"Are you dead, Nell?" she asks quietly, holding the door in her hand; "because if so, I'll send for the coroner."
"No," say I, blubbering noisily, and burrowing still farther into the dim blue squares of the old Kidderminster. "Worse luck—I wish to God I was."
"Are your bowels yearning still over the big wax doll?" she asks, jeeringly. "Have you retired into your chamber to weep there?"
"Yes," I say, angrily, lifting up my head, and pushing back my wet, fuzzy locks; "and since it is my chamber, and not yours—"
"You'd thank me to 'absquatulate,' as the Yankees say," interrupts she, laughing and showing the sweetest, shortest, whitest little set of teeth that ever set dentist at defiance. "Well, I will in a minute; but 'I have an errand unto thee, oh, captain.'"page: 148
"I wish your errand was to tell me that I was going to be hanged, or that you were; I'm sure I don't know which would give me the most gratification," growl I, squatting still Job‐like in the ashes.
"You're a little fool, my sweet Nell," says my sister, playfully. "I don't believe you'd relish a bit of whipcord round your little neck any more than I should; but really," she went on, gravely, "I wonder you have not more spirit than to be boo‐hooing about that scoundrelly longlegs; if any man had served me such a turn," she said, clenching her right hand into a small white ball, while her sleepy eyes woke up into beautiful fierce life, "I might have killed him, put a pinch of strychnine into his tea, or stabbed him in the back on the sly—indeed, I'm sure I should; but cry over him, put my finger in my mouth and pipe my eye, never, never, never!" (a crescendo scale, ending in fortissimo).
"If you talk of meanness," I cry, springing to my feet and stamping, "I wonder what can be meaner than selling yourself like a bale of goods or a barrel of beer, as page: 149 I'm doing. Oh, what do I care how mean I am! What sin is there so big that I would not commit it this minute, and commit it most gladly too, if I could but have him back here this minute in this room. Oh, he has not forgotten me! I know it! I know it! There's some mistake, I'm sure, and I shall find it out when it's too late—when I'm in hell!"
I fling myself down again, and cry aloud; my punishment seems greater than I can bear. Dolly walks to the window and looks out.
"Oh, Dick, Dick!" I groan, "where are you? where are you? Oh, my darling, are you dead? Oh, come back to me, for God's sake!"
I forget even Dolly's sneering presence, I forget my father, forget everything but that one man that made earth first heaven—then hell for me!
Dolly goes to the wash‐hand‐stand and pours some cold water into a basin.
"Stop, crying," she says, harshly; "you have made your bed, and you must lie on it. Sir Hugh is here again—of course he page: 150 has a right to come now; and you'd better try and bathe the swelling and redness out of your eyes, if we are to get any money out of him. You don't look a choice morsel to bribe any man with as you are now."
Her cold voice calls me back to myself. I rise and pick up my heavy cross, and prepare to stagger along a little farther under it. I sponged and mopped my face, and scrubbed it with a Turkish towel, and then I looked in the glass; and then I mopped and scrubbed again, and tried to persuade myself that I did not look as if I had been crying.
Half an hour after I am sitting on the green settee by the library fire, with the gentleman by whose library fire I am to sit through my life, with what patience I may.
His arm is round my waist, and he is brushing my eyes and cheeks and brow with his somewhat bristly moustache as often as he feels inclined—for am I not his property? Has not he every right to kiss my face off if he chooses, to clasp me and hold me, and drag me about in whatever manner he wills, for has not he bought me? page: 151 For a pair of first‐class blue eyes warranted fast colour, for ditto superfine red lips, for so many pounds of prime white flesh, he has paid down a handsome price on the nail, without any haggling, and now if he may not test the worth of his purchases, poor man, he is hardly used! As for me, I sit tolerably still, and am not yet actually sick, and that is about all that can be said of me. Presently the situation becomes too warm for me.
"May I move a little, please?" I say, edging away out of my owner's arms. "I'm rather—rather hot, please—the fire, I mean."
"All right," says he, cheerily; "it is a fire to roast an ox, isn't it? let's move the settee back a bit, and then we shall be all serene—shan't we, love?"
So we move the settee back into the shade, where the fire glow cannot reach us, but my blood does not grow any the cooler, for that accursed, girdling arm is still round me—my buyer's arm—that arm that seems to be burning into my flesh like a brand.page: 152
"Jolly this, isn't it?" whispers Strephon, chuckling; "and it'll be jollier still when we're married; it'll be always like this then."
When we're married! Merciful Heavens! If the prologue is so terrible, what will the play be?
"If you please," I begin again meekly; "I—I think I'd rather sit on a chair by myself; you—you—hurt me rather."
I remove myself, unopposed, to a distant chair, and breathe freer.
"I thought you promised you'd try and like me, Nell," says Hugh, rather ruefully, by‐and‐by.
"I will try, I will indeed," I cry eagerly, clasping my hands, "only—oh do, do give me time!"
"Give you time, indeed," says Strephon, grimly, glancing at his own weather‐beaten face in the glass; "all very fine, but I have not so much time to give; by the time you have made up your mind whether you like me or not, I shall be a drivelling old fool, past caring for any woman's liking."page: 153
I answered him to never a word, I agreed with him so fully as to his great age.
"One would think," pursues he, stalking up and down in a fume, "to hear you talk, that I had a humpback, or a club foot, or some great natural deformity;" and then he steps before me, and says with a certain rough pathos in his voice, "Won't you tell me, Nell, what there is about me so repugnant to you, that I may try and mend it?"
A terror seizes me; beaked Israelitish faces swarm before my mind's eye; am I recklessly tossing away salvation in the shape of those signed cheques on Coutts' Bank, that are lying in simple beauty on the table.
"Don't talk nonsense," I cry pettishly, giving my head a little ill‐humoured jerk; "when did I say there was anything about you repugnant to me? Cannot you understand that it is not so easy to get very fond of a person all in a minute, when you have not been thinking of anything of the kind before; I told you I'd try and like you, and I will: what more can I say? Oh page: 154 please, please have patience with me!" I cried, piteously.
"Haven't I been patient already?" he asks, sorrowfully. "I'm not an impatient fellow ever; it isn't my nature. I don't expect to sow and reap the same day, but I don't know how it is, you seem to like me less and less every time I come."
No answer: a guilty head hangs down low, lower, till it droops on a guilty breast.
"If," says Hugh, quite gently, though his honest face is working a little, as with some strong smothered emotion, "you feel that you can never have anything but a bare toleration of me, say so at once, child? I'm old enough and strong enough to bear a little disappointment; we can't expect to have everything our own way in this world, and I know I'm not quite the right cut to take a girl's fancy; it would be better you should speak out, while it's time, than that we should make each other miserable for all our lives."
I gaze long and earnestly into the fire, before I answer; watch the little firescapes crumbling, dissolving, and reform‐ reforming page: 155 ing, while my hot white hands twist and wrench and generally maltreat each other. Shall I take him at his word? Oh God! how delicious it would be; it would be like exchanging the fetid stifling air of an eastern dungeon for the free gales rioting under the blue April heavens.
Shall I get off the altar, where, (àla Jephtha's daughter, I am lying bound; slip the cords off my wrists, and walk lightly away? Shall I still be able to think of that laughing debonair glorious face, without stabs of despair—of those strong arms where I may yet find heaven, without deadly sin? Shall I defy the might of Israel? Shall I let the "hexecootion" have its way? Shall I kill my old dad? Never. For him I have begun this great sacrifice; for him I will complete it; for him I will go to hell. So I speak quite firmly, even though I feel myself paling to the lips—Sir Hugh's lips.
"No, I have said it, and I mean to stick to it; let us try and make the best of one another; it's a very puzzling world, and it's page: 156 very hard to know how to live through it; but I suppose if we try to do our best, it'll all come right in the end."
So I, in my despair.
Then he says, with some difficulty, and flushing scarlet, despite his nine lustres—
"If you're only marrying me on account of that dirty money—"
I interrupt him, hastily.
"Nonsense," I cry, "say no more about it; I mean to be your wife, and I suppose we shall manage to scratch on pretty much as other people do." But to my own heart I say that "I would that I were dead."


text:
Data System Management
Within the Division of Learning Services, the Office of Data System Management is responsible for the development and implementation of the Missouri Comprehensive Data System (MCDS) which will include the student-level record system. Core Data/Missouri Student Information System (MOSIS), a web-based data collection system of education-related statistics; and Grants & Planning, an instrument provided to schools to assist with federal grant applications and program planning. The MCDS also maintains the P-20 longitudinal data system used for research of student progress and achievement, postsecondary and workforce preparation, etc. The Office of Data System Management also coordinates school district data team training and certification regarding the use of data to improve classroom instruction. In addition, the office collects and generates data to meet federal reporting requirements and compliance, as well as provide data utilized in research and analysis that impacts policy decision-making.


text:
read reviews [2]
Serves 6
Papaya and pineapple juice build on the clean, sweet flavor of mango in this sorbet, while a splash of coconut milk smoothes its texture. If papayas aren't readily available or in season, just add another mango.
Working in batches if necessary, purée all of the ingredients in a blender until smooth. Transfer the mixture to a bowl, cover, and refrigerate until cold (about 2 hours). Freeze in an ice-cream machine according to the manufacturer's instructions. Transfer the sorbet to an airtight container and freeze overnight to finish setting. Take the sorbet out of the freezer and let it soften for about 5 minutes before serving. It will keep in the freezer for about two weeks.
Photo: Maren Caruso
FineCooking.com is a part of the Taunton Home and Garden Network
Taunton Home |
Books & Videos |
Contact Us |
Product recall information
Privacy Policy |
Copyright Notice |
Taunton Guarantee |
User Agreement |
About Us |
Work for Us |
Contact Us |
Advertise |
Customer Service
© 2017 The Taunton Press, Inc., Part of Taunton's Women's Network. All rights reserved.


text:
I was wondering the advantages or disadvantage of both.
I was wondering the advantages or disadvantage of both.
They both are great products. It all depends on what you are looking for.
I initially bought bumper boys because thunder only had five shooters, and I did not need that many. I quickly got sick of hauling, reloading, transporting, not being able to use other training equipment like wingers without needing different electronics.
Once thunder came out with two shooter, I sold bumperboys and immediately bought two.
I personally like the thunders better. Easier and quicker to reload. Easier to carry two into field with other things.
The only hard part is getting used to timing to properly prime the gas. Once you got that, they are easy.
Some people don`t like Thunders dummies,they are plastic.I`ve had no problems (we have 5 thunders).As far as priming ,yes our old Etch Marks can be tricky but the new Thunders are great,if you launch anytime between 5 and 15 seconds the throws are consistent.Flags on one and no flags on the same machine will result in inconsistency.
Got a couple Spiders coming and will give a review soon.Jim
I have dogtra receivers for my bird launchers so I can use them on the thunders so I have that expense done and living in NY could be a pain to get loads for the bumper boy in the future.
Had BB sold them and bought thunder. Would not go back. No issues, but did have some operational questions. Thunder was great to work with. BB customer service sucks.
Thunder timing does take a bit to get use to as mentioned.
Where can you buy these thunder launchers at?
gun dog supply sells them with free shipping. How often do you have to change the AA battery's in these launchers? I'm kind of torn between buying (2) BB or (2) thunder launchers. I like how BB has a "auto-run" option and how lite they are. But I Like how much cheaper the thunder launchers are and having better customer service is awesome. I already have Dogtra electronics so I dont have to worry about that cost.
I just got my new 5 shooter dropped off today. Can't wait to get it fired up!
__________________________________________________ _____________
Brownstone's Harley- "Harley" 7/29/2009 (By CH Woodhull's Roger That)
Maple Hill's Ella Enchanted QAA- "Ella" 8/30/2011 (FC AFC Land Ahoy x Stella's Duck Delivery MH)
Good Idea's The Cutting Edge- "Edge" 9/29/2014 (Grady x Good Idea's Touch of Class)
Joe Dutro
Oakwood's Dora Duky Desire MH- (Dora) 3/3/03- 3/16/11
Desire's Midnight Rose SH- (Rose) 1/29/08
Desire's Big Launch MH (Rocket) 9/29/09
Desire's Pine Ridge Lonesome Gus MH (Gus) 9/29/09
Desire's Littlest Hellian JH (Izzie)


text:
Because of the fabric your suit will last through many hours of pool time!
Made from Speedo Endurance Lite polyester fabric: 51% PBT and 49% polyester.
Posted by Unknown on 21st Mar 2013
I teach various aquatic exercise classes and the suit is comfortable and stays put. True to Speedo sizing as well. I am 5'6" and weigh 125 lbs. I bought this suit in a 36 and it's got a little room, but no baggy seat. Great for reaching, jumping and kicking exercises.
Choose a currency below to display product prices in the selected currency.


text:
Web Stories
Economist to present heterodox perspective on globalization, March 27
Posted March 21, 2003; 01:49 p.m.
for Whom? A Heterodox Perspective" is the topic for a lecture to be presented at 4:30 p.m. Thursday, March 27, in 15 Robertson Hall. Jomo K.S. (Kwame Sundaram), professor of applied economics at the University of Malaya, will present the talk, which is part of the Southeast Asia Lecture Series.
One of the most influential and prolific scholars in Malaysia, Jomo has written more than 30 monographs and edited some 40 books. He is on the board of the United National Research Institute on Social Development in Geneva and is the founding president of International Development Economics Associates.
The Southeast Asia Lecture Series is sponsored by the Center of International Studies , the East Asian Studies Program , the Council on Regional Studies , the Graduate School and Foreign Policy in Focus.
Contact: Tom Bartus (609) 258-3601


text:
Call 1.888.468.5511
Email firstname.lastname@example.com
We've negotiated prices so good, our brand partners don't allow us to share them with people who aren't members of GovX.
Join or log in to see prices and shop.
Benchmade Knife Company, Inc. warrants to the original owner that Benchmade knives purchased from authorized dealers will be free from defects in materials and workmanship. Benchmade will without charge, repair or replace at our (Benchmade's) option, any knife returned for Warranty work and found to be defective by Benchmade. The Benchmade Lifetime Warranty only applies to genuine Benchmade products from authorized Benchmade dealers (GovX is an authorized dealer). Benchmade also will gladly re-sharpen your Benchmade knife to a factory razor sharp edge (service does not apply to any serrated portion of the blade). If you prefer Benchmade to sharpen your blade, or if you may have neglected to maintain your edge for a while, simply ship your knife to them. They'll not only sharpen it, but will also inspect the knife for any warranted repairs and "tune" the knife for optimum performance. For more information and to contact Benchmade regarding a warranty/sharpening visit: https://www.benchmade.com/warranty-service
Benchmade products are made to order and can take 4 weeks or more to process and ship.
RETURN INFORMATION GovX and Benchmade strive to provide the best customer service possible. Benchmade merchandise can be returned for a full refund minus a 20% restocking fee within 30 days of the delivery date, provided the product is in new, unused condition. If you need to return an item you ordered with GovX.com, contact one of our Customer Support Team members at 888-468-5511 to obtain a Return Authorization Number and return the item within 30 days of delivery *(Do not contact manufacturer directly. All returns must be processed through GovX). ALL RETURNS MUST HAVE A RETURN AUTHORIZATION NUMBER that can only be provided by contacting Govx.com at 888-468-5511 or by emailing us at firstname.lastname@example.com. *Keep the following guidelines in mind: (i) all items must be returned in new, unused condition, and will undergo quality checks. All product packaging materials--including boxes, manuals, warranty cards, instructions, tags, and any other materials in the original shipment--must be returned with your returned item(s), (ii) our return policy is subject to each Manufacturer-Partner's individual return policy, which may vary from the GovX policy, in which case, the Manufacturer-Partnerss policy prevails (See BENCHMADE RETURN INFORMATION below), and, (iii) we do not cover postage expense on returned items unless there are special circumstances which will be explained when you call us to arrange for your return. BENCHMADE RETURN INFORMATION All returns must have a return authorization number. We recommend selecting a trackable shipping method and keeping the tracking information for your records until the return/exchange is complete. Refunds/exchanges can take up to 3-4 weeks or sooner. Shipping charges are not refundable. We do not accept COD deliveries. If possible, use the original shipping package for returns and exchanges. EXCHANGES We do not process exchanges. To exchange an item, please return the item pursuant to the Return Authorization number and instructions you obtain from us, and place a new order on GovX.com.
©2017 GovX | Terms of Service | Privacy | Sitemap


text:
A colorful four-term Louisiana governor has landed a docu-series on A&E. The Governor's Wife will star 85-year-old Edwin Edwards and his 34-year-old wife, Trina, along with several of their children from previous marriages. Edwards served four times as Louisiana's governor over the course of three decades, and also served eight years in federal prison for crimes committed while he was in office. In 2001, Edwards was convicted on bribery and extortion charges. He became pen pals with Trina during his prison stint and they married after his release last year. The show will focus on Edwin and Trina's May-December relationship and follow Edwin's daughters (Anna, a 62-year-old, four-time divorcée and Victoria, a 60-year-old ex-showgirl) along Trina's sons (Logan, 15 and Trevor, 13). Some official description: "The series follows Trina as she attempts to fit into the former governor's upscale world and busy social life while trying to get along with daughters twice her age and corral her teenage sons. Between school projects, running for president of the Homeowner's Association, fending off skeptics who think she's a gold digger, and thoughts of adding a baby of their own to the mix, the Edwards clan truly represent a new take on the modern family."
quote:Will he be off of probation by then?
Edwards in 2015, we are a 200 year old state we can have a 90 year old governor.
Convicted felons can't run for office.
and thoughts of adding a baby of their own to the mix,
Edwards in 2015, we are a 200 year old state we can have a 90 year old governor.
The Governor's Wife will become the latest Louisiana-set reality show. The state has been a hotbed of reality filming in recent years, led by A&E's own ratings phenomenon Duck Dynasty. There's also History's Swamp People and Cajun Pawn Stars; Discovery's Sons of Guns; Spike's Rat Bastards; CMT's Bayou Billionaires and My Big Redneck Vacation, among others
quote:man, some butt hurt folks in this thread - EWE scoring like a boss and the penis envy bitches be cryin'-
Gov. Edwards and 34 yr old wife, Trina, in new A&E reality show
Advertising Info
Privacy Policy
Where to Watch LSU
Contact Us
© 2017 TigerDroppings.com. All Rights Reserved


text:
Bill proposing online sales tax gets mixed reviews
LA CROSSE, Wis. - Lawmakers are currently debating a bill that would allow states to collect sales tax for online purchases.
Right now, states can only require businesses to collect online sales tax if there is a physical store in the state.
Under the bill, if a shopper makes an out of state purchase online, the sales tax collected would have to be sent the state where the shopper lives.
Last year, Wisconsin had $142-million of uncollected sales tax for online purchases according to a new USA today report.
While that could mean more money out of consumer's pockets, it's not necessarily a good thing for every business.
Kroner's True Value Hardware Store in La Crosse is one of the last remaining stores of its kind.20055350
"They're a dying breed, but we're trying to plug along," said Bill Kroner, manager of the store.
The store has been selling general goods for more than a century.
In 145 years, everything from the doors, to the drawers and the creaking floors have all stayed pretty much the same.
"We updated the lighting a little while ago," said Kroner.
Technology has helped business run a little smoother, but the store doesn't have enough resources to maintain an online website.
Kroner said charging sales tax for online purchases would help businesses like his compete.
"It would help us as a retailer, and make it a more level playing ground for someone offering someone the same thing I've got, I have to charge them 5 and a half percent tax," said Kroner. "Why shouldn't they?"
At Dave's Guitar Shop in La Crosse, it takes Tim Mullally only seven minutes to snap a picture of a product and put it online.
"And there is that guitar on our website," Mullally said after finishing a post.
That's actually more time than it takes for a product to sell anywhere in the world.
"There have been times where I literally hit the upload button and there has been a purchase for that guitar within less than a minute," said Mullally.
About 80 percent of the business is online.
"It's going to hurt," owner Dave Rogers said about the bill. "It's going to sting yeah for sure."
Rogers said incorporating online sales tax would make a huge difference in business.
"If you added 5 percent on that, the money collected, if its collected for the state would be huge," said Rogers.
He said the change would take a little getting used to if the bill passes.
"We'll all suffer a little bit and orders are going to lag, and then people are going to realize well if you want it, you've just got to pay," said Rogers.
Rogers said theoretically, it makes much more sense and save more money if he only ran an online business, but he said there is some value to having customers come into the store.
Kroner said he may start selling products online in the future in order to keep up with business.
The bill passed in the Senate on Monday with a 69 to 27 vote.
It's now on its way to the House where some lawmakers say it will have a tougher time getting passed.
Latest News
- Walker hopes federal government shutdown can be avoided
- Baldwin encourages Perdue to visit Wisconsin dairy farmers
- Bills to fight homelessness in Wisconsin up for vote
- Proposal would allow homemade baked goods sales in Wisconsin
- Wisconsin dairy farms face closure due to Canadian policies
- Walker says he has 'no interest' in higher vehicle fees
- CSAs connecting fresh produce to consumers
- La Crosse 12-year-old to clean up skate park with community help
- Thousands honored in La Crosse for volunteering
- Mom who made kids sleep in feces-covered room gets probation


text:
News Search Results for "Advocacy"
Advocacy Update: Sprint to the Finish
David Lancaster, Hon. AIA, updates us on the 85th Legislative Session's sprint to the finish.
Advocacy Update: State vs. City
TxA's Senior Advocate, David Lancaster, Hon. AIA, sheds some light on the tug-of-war between state and local power that has arisen this legislative session.
Advocacy Update: Relevant Bills
David Lancaster, Hon. AIA, tells us about the bills architects should watch during the 85th Legislative Session.
This Week in Advocacy— HB 2170: Where Does Implied Warranty Belong?
David Lancaster takes a closer look at implied warranty and HB2170.
Architects Day Roundup
On February 7, Texas architects descended on the Capitol for a day of legislative action (and snakes!).
Legislative Preview
With a new legislative session just beginning, David Lancaster, Hon. AIA, Senior Advocate, runs down some issues that could impact architects during this year's Regular Session, which runs through Memorial Day.
Top 5 Reasons YOU (Yes, You) Should Go to Architects Day
Wendy Heger, AIA, provides the top 5 reasons to attend Architects Day.
2017 Architects Day
Architects Day will take place on February 7. Architects from across the state will converge on the Texas Capitol to meet with legislators to promote the importance of architectural design for urban planning. Register today to help us spread our message.
BLOG | Update on the Dallas Trinity Toll Road Controversy
On April 16, the Dallas City Council voted to move ahead on plans for implementing a revised vision for the Trinity Parkway. Bob Meckfessel, FAIA, traces the history of this controversial project and the role architects have played in advocating for a more sustainable, context-sensitive design.
Who Will Advocate for Architecture?
Will your House and Senate districts be represented at Advocates for Architecture Day? The highlighted areas show districts with architects already registered to advocate on February 10. Join them in Austin for a fun day at the Texas State Capitol on behalf of your profession.
Sign up today to ensure your district is represented. Everyone is important!
Advocacy Update: Understanding Texas' Political Climate Linked Documents
Texas Society of Architects EVP James T. Perry shares a document with details on the 2014 general election, a summary of primary elections, and an overview of budge and tax-related issues to aid you in understanding of the current Texas political climate.
BLOG | Beyond the Boardroom: Looking Ahead in 2014
Executive Vice President James T. Perry reports on staying up to date with AIA developments, legislative efforts to reduce the architectural threshold, and other activities the Society is looking forward to in the coming months.
BLOG | Advocacy Update: Robinson Wins!
Texas Architect David W. Robinson, AIA, was elected to the Houston City Council in a Dec. 14 run-off. The Society's Senior Advocate David Lancaster, Hon. AIA, reports on the race.
Texas Architects' IgCC Roadmap
Over the past four years, Texas Architects has monitored and participated in the development of the International Green Construction Code (IgCC), and provided significant input into its refinement and development. Our IgCC Task Force has developed this Road Map to guide those officials contemplating or actually adopting the IgCC.
BLOG | Advocacy News: AIA Announces 2014 Call for Issues Survey
James R. Nader, FAIA, a Texas representative to the AIA Board Advocacy Committee, invites you to share your views on the AIA policy issues that matter most by taking the 2014 Call for Issues Survey. We appreciate your help in shaping the message that AIA takes to Capitol Hill next year.
Everyday Advocate
"The effects of advocacy can be as far-reaching and as long-lasting as a great design." El Paso's Melissa C. Brandrup, AIA, shares her experiences as a participant in Advocates for Architecture Day 2013, and makes it her personal charge to help others learn why design matters.
Advocates Show Legislators that "Design Matters"
There was a great deal of quality advocacy taking place in Austin on Tuesday, January 29. Approximately 150 Texas architects stormed the Capitol to promote the profession's legislative agenda as part of Advocates for Architecture Day 2013.
Advocacy Update June 2012
Election Day brought big news—some good, some bad.
Some very good news was Bill Wilson, FAIA, making a run-off in his race for the HD 43 Republican primary. It's noteworthy that Wilson ended in a virtual tie with one of the three candidates in that race, especially since he was outspent 3-1 by one—his remaining opponent in the July 31 run-off.
Texas Architects Committee Update
The Texas Architects Committee (TAC) update as of December 31, 2011.


text:
» Drug, Devices, and Supplements
» Physician Accountability
» Consumer Product Safety
» Worker Safety
» Health Care Delivery
» Auto and Truck Safety
» Global Access to Medicines
» Infant Formula Marketing
December 2, 1998
Peter Lurie, M.D., M.P.H.
Sidney M. Wolfe, M.D.
After years of criticism from the drug industry that the drug approval process was too slow, the U.S. Congress passed the Prescription Drug User Fee Act (PDUFA) in 1992. The Act authorized drug companies to pay user fees to the FDA for the agency to hire more Medical Officers to speed up the review of new drugs. One result of this has been that larger numbers of drugs are now being approved. Whereas in 1995 28 new drugs were approved, similar to the numbers in previous years, in 1996 the number of new drugs approved had risen to 53; 39 new drugs were approved in 1997. However, these fees cannot be used to hire more people to monitor for adverse drug reactions, even as larger numbers of new drugs come on the market.
At the end of 1997, the Congress reauthorized PDUFA and passed the Food and Drug Administration Modernization Act (FDAMA), which permitted drug approval based on a single clinical trial (instead of two), codified and expanded the use of "accelerated approval" mechanisms for drugs for life-threatening conditions, and established the use of surrogate endpoints in clinical trials. It also included a number of mechanisms for speeding FDA review.
While much of this has been good news for the industry, it is becoming increasingly clear that patients are paying the price. In the past year, a record three new drugs have been removed from the market due to serious safety problems: dexfenfluramine (Redux), mibefradil (Posicor) and bromfenac (Duract). For all three, data available prior to approval indicated potential safety problems. Industry profits handsomely from this stream of new drugs, most of which offer no therapeutic benefit over already approved drugs and which may have less expensive generic counterparts.
When a New Drug Application (NDA) is submitted to the FDA, it is usually assigned a single Medical Officer, a physician responsible for coordinating the reviews of the drug by other FDA employees, including chemists, toxicologists, pharmacologists and statisticians. The Medical Officer reviews the clinical trials in detail and makes a recommendation as to whether the submitted data support approval of the drug. No FDA employee is more familiar with the entirety of the NDA than the Medical Officer who reviews the application. When the new drug is sufficiently advanced in the review process, the data are usually presented to an Advisory Committee, a panel of outside experts who advise the agency and whose recommendation the agency usually follows.
The opinions of Medical Officers on the recent changes in the review process are thus of great importance, but are seldom heard. One Medical Officer felt obligated to write a letter to the Washington Post on August 24, 1998 in order to voice his concerns about the new drug approval process. He was then asked to resign for having written the letter, but that request was later withdrawn. We undertook this survey in order to determine the opinions of those most intimately familiar with the impact of changes in the FDA review process, the Medical Officers.
In late July 1998, we obtained a list from the agency of all 216 Medical Officers in FDA's Center for Drug Evaluation and Research (CDER). We eliminated 22 Medical Officers who are the Directors or Deputy Directors in CDER or who direct the reviewing Divisions. An additional 21 Medical Officers were excluded because they are in the Office of Scientific Investigation, which investigates potential improprieties in clinical trials, or are responsible for such agency functions as statistics, epidemiology or surveillance. These Medical Officers do not review NDAs. One Medical Officer was known to have left the agency. This left a total of 172 potential respondents.
In order to maintain the confidentiality of respondents as much as possible, we searched phone books and the Internet for home mailing addresses for the Medical Officers in the metropolitan Washington, DC area. We identified home addresses for 108 (63%) of the Medical Officers and used mailing addresses at the FDA for the remaining 65 Medical Officers.
Each Medical Officer received a cover letter explaining the purpose of the study. We designed a seven-page questionnaire for the Medical Officers to complete and return to us by mail. The survey explored seven general areas: 1. Whether there was pressure on the Medical Officers to approve drugs more rapidly; 2. Whether there was pressure on the Medical Officers to approve a greater proportion of new drugs; 3. Whether drugs were being inappropriately shifted into the "accelerated approval" track; 4. Whether studies were obtaining FDA approval only because post-marketing studies were required; 5. Whether FDA standards for safety and efficacy had been lowered; 6. Whether inappropriate internal or external pressure was being placed upon Medical Officers to approve drugs; and 7. Whether drugs they had reviewed had been inappropriately approved or disapproved in the last three years. The questionnaire did not ask for the names of specific drugs, as this would have compromised the Medical Officers' confidentiality, but they were invited to provide their reviewing division if they so chose. A series of questions on the use of placebos in clinical trials were not used as the Medical Officers' responses indicated that those specific questions were not sufficiently clear.
We mailed the questionnaires to the Medical Officers on three occasions in September and October 1998. Because the Medical Officers were not asked for their names, we were unable to distinguish between those who had and had not responded, so all received three mailings. However a code on the return address envelope allowed us to determine to which mailing the Medical Officer was responding and whether the questionnaire had been mailed to his or her home address or to the FDA.
Responses were entered into FoxPro for analysis. If the respondent indicated that a drug they were reviewing fell into a particular category but failed to mention the number of such drugs, we assumed that only one drug fell into that category for that reviewer, as "one" was the most common response to these questions. Due to the large number (and sometimes great length) of responses received to qualitative questions, only representative comments are included in full in the text.
Sixty-five percent of the responses received were from the first mailing, 27% from the second and 8% from the third, for a total of 53 responses (31% response rate). The response rate for those receiving the questionnaire at home was 28% and for those receiving it at their FDA office was 35%. Twenty-five Medical Officers voluntarily provided their reviewing division; the respondents were drawn from a minimum of 11 of the FDA's 15 reviewing divisions.
Nineteen Medical Officers identified a total of 27 new drugs that they had reviewed in the past three years that they thought should not have been approved but were approved (Figure 1). Due to possible under-reporting, this is a minimum estimate of the number of drug approvals that the Medical Officers consider inappropriate. Fifteen Medical Officers indicated that they had reviewed one drug that had been inappropriately approved; three mentioned two drugs; and one said that six drugs he or she had reviewed had been inappropriately approved. In marked contrast, five Medical Officers identified only six drugs that they thought should have been approved, but were not.
The Medical Officers were asked how they thought the standards of safety and efficacy now in existence compare with those existing prior to January 1995 (Figure 2). Seventeen of 36 Medical Officers (47% of those responding) described the current standards as "lower" or "much lower," 13 (36%) described them as "about the same" and six (17%) described them as "higher." None described the standards as "much higher." (The smaller number of Medical Officers responding to this question was presumably due to some Medical Officers only having been hired in 1995 or later.) Of the 17 Medical Officers who stated that a drug they had reviewed should not have been approved, 11 (65%) stated that current FDA standards were "lower" or "much lower."
The following are representative of the Medical Officers' comments on the issue of standards for FDA new drug approval:
"We are shifting the burden of proof on safety onto ourselves. Instead of asking the drug companies to prove the drug safe, we are trying to prove the drug dangerous. If we cannot show that the drug is dangerous, then it is assumed safe."
"We are told that approvability is our goal with 'problems' to be addressed in labeling."
"Efficacy criteria should include clearly evident benefits. Obvious example is Redux: little efficacy for weight loss; no evidence for health benefits; high degree of questionable safety in areas of pulmonary hypertension and neuropathology."
"I am very much concerned about lower standards for safety, in particular, the size of safety data base required prior to marketing. I am very much concerned that there now appears to be support for a single study to demonstrate efficacy. I believe this 'mutual confirmation' [by two studies] greatly reduces the possibility that an inaccurate conclusion or inference of efficacy will be made."
"The standards are good if it comes to simply identifying a problem or determining how well a drug works. However, implementation is a problem. So often, we identify a problem pre-approval, and it is simply inserted into the label with everything else the practitioner has no time to read."
"Efficacy standards are definitely lower. Safety review standards are higher, but then when there is found to be a safety problem we approve the drug. There is no more a judgement of benefit to risk ratio, as there was for so many years."
"The agency is allowing a lot of 'me-too' drugs on the market some of which are less safe or less efficacious than existing drugs already approved and marketed in that drug class."
"These are value judgements. Each case is open to many considerations and criticism depending on one's perspective. In general, the FDA standards are the same as in other jurisdictions."
"I don't think that the FDA standards have been lowered. If any change has occurred, it has been in the direction of demanding higher standards of safety and efficacy."
"In some aspects the safety review is improving due to electronic submissions and investment in software to review safety data submitted electronically."
"I believe the training given reviewers now is far better than previously and that staffing has also improved."
Twelve Medical Officers identified 25 new drugs that they reviewed in the past three years that they believed had been approved too fast (Figure 3). Eight Medical Officers identified one such drug, two mentioned four drugs and one Medical Officer apiece specified three and six drugs.
Thirty-four of 38 Medical Officers responding (89%) stated that the pressure on them to approve new drugs was "somewhat greater" or "much greater" compared to the period prior to 1995 (Figure 4). None answered "somewhat less" or "much less." (Again, the smaller number of Medical Officers responding was presumably due to some Medical Officers only having been hired in 1995 or later.) Asked to identify the source of the pressure to approve drugs more rapidly from a list of yes-no options, 26 (68%) identified the Center for Drug Evaluation and Research Office, 19 (50%) the Congress, 18 (47%) the pharmaceutical industry, 14 (37%) the Office Director, 13 (34%) the Division Director and 11 (29%) the Team Leader. (Because some Medical Officers identified more than one source of pressure, the percentages exceed 100%.)
The Medical Officers were also asked about pressure on other Medical Officers to approve new drugs more rapidly (Figure 5). Thirty-five of 38 Medical Officers responding (92%) described the pressure on other Medical Officers to approve new drugs more rapidly as "much greater" or "somewhat greater," two (5%) described this pressure as "about the same" and one (3%) described it as "somewhat less."
The Medical Officers also offered comments on the issue of the speed of new drug approvals, including the following:
"Rapid approval often means insufficient time to examine carefully original data, accepting 'on faith' validity of randomization, screening, use and misuses of inclusion and exclusion criteria. There is insufficient time to discuss outlying observations."
"The official times allowed for the review process keep getting shorter and shorter. The recently passed 'FDA Modernization Act' is making things a lot worse."
"Medical Officers don't approve NDA's. We simply recommend for or against approval. Office Directors make the final decision."
"[Deputy Center Director for Review Management Murray] Lumpkin and [Director of the Center for Drug Evaluation and Research Janet] Woodcock are mainly interested in counts of approvals, time to approval and not quality."
"FDA approvals of drugs at a fast speed are without question more risky than before (slow approvals) but faster approvals have had a positive public health impact on the treatment of life-threatening diseases (AIDS and cancer)."
"In my division the accelerated approvals were justified and resulted in a measurable health benefit."
"Long overdue. I do not believe that the decreased approval time has necessarily compromised safety. The system was too open-ended previously."
"Improved computer support, information technology, communication technology and better staffing have greatly enhanced the speed at which we can work and review applications in less time today than prior to 1995."
Nineteen of 33 Medical Officers responding (58%) stated that the pressure on them to approve a greater proportion of new drugs was "somewhat greater" or "much greater" compared to the period prior to 1995 (Figure 6). Thirteen (39%) said that the pressure was "about the same" and one (3%) described the pressure as "somewhat less." The sources of this pressure were identified from a series of yes-no options. Thirteen Medical Officers each identified the Office Director and the Center Office (39% each), 10 (30%) the pharmaceutical industry, nine (27%) the Congress, eight (24%) the Division Director and six (18%) the Team Leader.
The Medical Officers described similar pressures upon their colleagues (Figure 7). Twenty of 32 Medical Officers responding (63%) described the pressure upon other Medical Officers as "much greater" or "somewhat greater" than in the period prior to 1995, with the remaining 12 describing that pressure as "about the same."
The following were among the Medical Officers' comments on the issue of approving a greater proportion of new drugs:
"We are in the midst now to approve everything but to describe drug weaknesses in the label. As one high ranking official said 'Everything is approvable. We can use the labeling creatively to lower the problems.'"
"Pressure to approve comes largely from the Office and Center level. Decisions should be left with the Division -- that is where the expertise is."
"Borderline drugs are being approved with the correct labeling and rectifying many deficiencies (safety) of products."
"What are the options; everything must now be 'approved' or approvable."
"In the last two years, I recommended that two drugs not be approved. They were both approved without consulting me. This never happened before. In one case, the drug did not meet the standards set up by the division, so they nullified the standards."
"I personally do not use or prescribe new drugs/vaccines unless they have been on the market 2-3 years in U.S. (Though I don't work with cancer, AIDS, etc.)."
"Not all drugs that are reviewed more quickly are approved; one can also reach a decision not to recommend approval more quickly than in former years."
"If we are approving a greater proportion of NDAs it would be the result of improved communication and collaboration during the pre-NDA process."
"The public (clinicians and patients) are served better when there are more options for treatment. The risk/benefit ratio should be recognized by all in order to take full advantage of more drug availability."
Seventeen Medical Officers identified a total of 28 new drugs in the past three years for which they were the primary reviewer that in their opinion had only been approved because post-marketing studies were required (Figure 3). Ten Medical Officers identified one drug, five identified two drugs and one each identified three and five drugs.
Eleven of the 32 Medical Officers (34%) responding stated that, compared to the period prior to 1995, the frequency of drugs being approved that would not have been approved without requiring post-marketing studies was "somewhat more common" or "much more common" (Figure 8). Twenty Medical Officers (63%) described this frequency as "about the same" and one (3%) described it as "somewhat less common."
The Medical Officers' comments on the issue of relying on post-marketing studies for approval included the following:
"We don't trust that the companies will carry out Phase IV studies with due diligence, either before or after PDUFA."
"Post-marketing studies are frequently not completed. FDA has no power to ensure such commitments. Drugs have been marketed before post-marketing protocols have been reviewed. I can think of only one such study that was designed properly and is being conducted reliably--metformin."
"Good idea but no way to enforce Phase IV studies. If sponsors don't do them correctly what recourse does FDA have? It's tough to pull a drug."
"The agency forfeits its most powerful weapon -- withholding approval. Essentially all Phase IV studies which are required are for safety reasons. If a problem is identified, the agency negotiates with the company for labeling changes. Withdrawal is extremely unlikely even if its problem is very serious."
"Post-marketing surveillance done by the sponsors is inadequate as is post-marketing surveillance at FDA -- this is one area of the agency that could really be improved."
"There are no teeth in post-marketing agreements."
"I think that all drugs should have a large randomized safety study at approval focusing on death and serious events occurrence. If properly designed, the cost would be reduced and not too great."
"Post-marketing is often necessary to examine aspects of a drug that seems safe and effective and should become available for use but may have not had adequate testing. All drugs can have more serious events that may not be revealed in clinical trials."
"I have not seen drugs approved based on Phase IV commitments."
Nine Medical Officers identified 19 new drugs that they had reviewed in the past three years that in their opinion had been inappropriately shifted to the accelerated approval track (Figure 3). Five Medical Officers identified a single drug that had been inappropriately shifted to the accelerated approval track, one identified two drugs, two identified three drugs and one identified six drugs.
Thirty-six of 50 Medical Officers (72%) reported that they "somewhat disapprove" or "strongly disapprove" of permitting drugs to receive accelerated approval strictly on the basis of having a unique mechanism of action (Figure 9). Seven (14%) each stated that they "neither approve nor disapprove" or "somewhat approve."
The Medical Officers made the following additional comments on the issue of shifting drugs to the accelerated approval track:
"Some drugs need to be in the accelerated approval category, although this should not be based on a unique mechanism of action."
"The industry is more and more aggressive to get their NDA designated for 'priority review.' We have to fend off those inappropriate ones with considerable resources."
"This is a formula for disaster. The patient doesn't benefit. A prime example is Fosamax touted as a 'gold standard' yet of questionable value. Another is tamoxifen for 'prevention' of breast cancer, but not yet fully available. Still another--Viagra."
"It is particularly in the case of drugs with new mechanisms of action that unanticipated safety problems are likely to occur. These are drugs that should not be subjected to accelerated approval."
"I think it is abused by companies for marketing reasons, when the benefit to public health (or some small subset) will be minimal at best."
"Should be reserved for life-threatening or incapacitating conditions for which there are no other treatments."
"Drugs for serious pain or other critical conditions that have 'unique mechanisms' and treat conditions for which no adequate therapy is presently available deserve accelerated status."
"Accelerated approval regulations are very carefully written and appropriate balance provided for population needs and demonstrating safety and efficacy. It is the application of the [regulations] that will be the true test."
"This has been one of the most recent successes of the FDA. I lived through the days when AIDS activists criticized us for being paternalistic and not allowing them (AIDS patients) to have access to new drugs. Patients were willing to take risks and we were in their way. Accelerated approval brought to them many new drugs that have increased survival time."
Nine Medical Officers reported a total of 23 inappropriate phone calls in the past three years regarding a new drug they were reviewing (Figure 10). Four Medical Officers reported one phone call, one reported two, three reported four and one reported five inappropriate phone calls, usually from the sponsor. Only one inappropriate visit (by a sponsor) was reported during that period.
The Medical Officers made the following additional comments on the issue of inappropriate phone calls and visits:
"My feeling after more than 20 years at FDA is that unless drugs can not be shown to 'kill patients' outright then they will be approved with revised labeling and box warning."
"Supervisors and administrators--from Congress re: myotropin [a drug for amyotrophic lateral sclerosis]."
"I heard of one Medical Officer who is said to have quit because of pressure from Capitol Hill about a controversial drug."
"Fortunately, there has been none, and I would be very resistant should any be made."
"I am not aware of any inappropriate external pressure on FDA Medical Officers. In my eight years of FDA experience I have never been confronted with inappropriate external pressure. This is one of the issues I treasure the most about being a Medical Officer: My decisions are strictly scientific. They are based on data. I have not had political or economical pressures of any kind."
"I haven't heard of a single such case in my division."
Eight Medical Officers reported 14 instances in the past three years in which they had been instructed, usually by the Office Director, not to present their own opinion or data to an FDA Advisory Committee when to do so might have reduced the likelihood that a drug would be approved (Figure 10). Five Medical Officers reported one such occurrence, one reported two occurrences, and one person each reported three and four occurrences.
The following were among the comments offered by the Medical Officers on the issue of withholding opinions or data from FDA Advisory Committees:
"There is a Center effort or at least a discussion to prevent the Divisions from offering opinions."
"The Advisory Committee (or anybody) don't pay much attention to what the primary reviewers say."
"I was 'guilty' of expressing my opinions before the Advisory Committee of our Division and several others for whom I wrote consultative reviews before 1995. I have not been asked to present reviews since."
"A Medical Officer must be forceful on safety concerns."
"The default appears to be 'yes' [to approval]; the hurdle to disapprove a drug is much higher than approving a drug."
"The Advisory Committees are increasingly pro-approval in recent years."
"It depends if management has been 'for' or 'against' drug approval. In my case they were supportive of my comments since there were problems with drug efficacy."
"I find the agency and its supervisory staff to be quite willing to discuss issues with Medical Officers, even if their views differ. The exchanges I have had have been most informative--both ways. At some times I have made my point; other times I learned something that caused me to change my views."
"In retrospect, I think the 'instruction' ... was appropriate and contributed to the scientific quality of my presentation."
"Never [been told to not present data or own opinion at an Advisory Committee meeting]. It would be against our policy and procedures to do so."
Thirteen Medical Officers identified 18 occasions in the past three years when a supervisor, usually their Division Director, asked the Medical Officer to change his or her opinion to agree with the supervisor's (Figure 10). Nine Medical Officers reported that this had happened once, three reported it had happened twice and one person reported three such episodes. Nine of the 13 Medical Officers indicated the direction in which they had been asked to change their opinion, and seven of these were in the direction of approval.
Medical Officers who said that a drug that they had reviewed had been inappropriately approved were almost twice as likely to describe at least one form of pressure described in this section compared to Medical Officers who did not think a drug they had reviewed had been inappropriately approved (Relative Risk for inappropriate pressure = 1.84; 95% confidence interval: 1.02-3.31).
The Medical Officers' remarks on the issue of being pressured by supervisors included the following:
"Superiors will try to get reviewers to change his/her mind so that they will not need to take the heat if something goes wrong. They have the option to override and should be willing to do so in writing."
"My office director told me that he was going to overrule me because the sponsor (Wyeth-Ayerst) would just go over our heads to Capitol Hill. He felt it was best to approve the drug for an indication not studied and have the sponsors do a Phase IV post-marketing trial in support of the indication. I reminded him that this sponsor had failed to honor other Phase IVs. He went ahead and approved the drug."
"Our superiors don't put pressure on us. They just ignore our opinion and write their own memo."
"I feel free to express and argue my views and position, even thought I do not always persuade."
"My interactions with supervisors have been marked by disagreements about different issues that we discuss and even argue about but I have not felt that they were pressuring me one way or another. Half the time I was right, half the time I was wrong. The free discussion of the issues led us most of the time to make the right decisions or decisions that if wrong, didn't have a major public health impact. Most of the decisions are reached by consensus."
Changes in the FDA review and approval process in the past several years appear to have led to a significant decline in the safety and efficacy standards for new drugs. Many drugs that have come on the market in the past three years have done so despite the opinion of the Medical Officer reviewing the drug that the drug should not have been approved. Said one Medical Officer: "My feeling after more than 20 years at FDA is that unless drugs can not be shown to 'kill patients' outright then they will be approved with revised labeling and box warning."
These findings should raise a red flag that the very integrity of the drug approval process in the United States, long an example to the rest of the world, is being seriously eroded. It is inexcusable to, in effect, override the opinion of the person most familiar with a drug's safety and efficacy data in many cases and approve the drug.
Top FDA officials have asserted that the reductions in reviewing time that date back to the early 1990s have not resulted in the lowering of safety and efficacy standards. Yet the opinions of many Medical Officers testify otherwise. Seventeen Medical Officers responding to our survey believe that the standards for safety and efficacy have been lowered, with only six believing they have been raised. One Medical Officer put it this way: "[Deputy Center Director for Review Management Murray] Lumpkin and [Director of the Center for Drug Evaluation and Research Janet] Woodcock are mainly interested in counts of approvals, time to approval and not quality." Because about half of the Medical Officers did not state their Division (in order to protect confidentiality, we had emphasized that providing such data was optional), we cannot speculate as to whether standards or practices may vary between or within Divisions.
Senior officials at the FDA have also asserted that the shortening of review times is the result of improved efficiency, in part due to electronic NDA submissions, and some Medical Officers echoed that assertion. While this may have some credence, the responding Medical Officers identified 25 new drugs that they said had been approved too rapidly in the past three years and the vast majority of those responding described greater pressure to approve drugs more rapidly. In these circumstances, it is no surprise that unsafe new drugs seem increasingly to be slipping through the FDA safety net.
The study also demonstrates that inappropriate pressure from Congress, the drug companies and senior FDA officials create an atmosphere in which the likelihood of drug approval is maximized. The pressure takes the form of inappropriate phone calls, pressure to withhold data or personal opinions unfavorable to the drug from FDA Advisory Committees, and pressure from supervisors on Medical Officers to change their opinion in the direction of approving the drug. One Medical Officer reported that another Medical Officer had resigned "because of pressure from Capitol Hill about a controversial drug." While some FDA employees reported that they had not experienced these kinds of pressures, the only acceptable number of inappropriate phone calls or instructions to withhold data from Advisory Committees is zero. Together, these forms of coercion threaten to undermine the scientific credibility of FDA reviews and to reduce the public's trust in the agency.
Three additional areas of concern were identified by the Medical Officers. The first is the apparently growing use of the label to address safety concerns and facilitate approval, instead of denying approval. One Medical Officer quoted a high-ranking FDA official as saying "Everything is approvable. We can use the label creatively to lower the problems." This represents a complete abdication of responsibility by the agency, particularly because it is well known that few physicians actually read the label. Second, at least some drugs have received approval by deferring unresolved questions to a post-marketing study to be done by the drug company. But, as the Medical Officers made clear, these studies are often of poor quality or not carried out at all. The result is drugs coming onto the market with unresolved questions, usually safety issues. Finally, it is clear that many Medical Officers feel that their opinions are being overlooked, even though they are most familiar with the data on the particular drugs they are reviewing. As one Medical Officer put it, "The Advisory Committee (or anybody) don't pay much attention to what the primary reviewers say." Said another: "In the last two years, I recommended that two drugs not be approved. They were both approved without consulting me. This never happened before. In one case, the drug did not meet the standards set up by the division, so they nullified the standards."
The main criticism likely to be leveled against this report is that the respondents were more likely to be critical of FDA than non-respondents. But, it is also conceivable that Medical Officers wishing to support the agency would have been particularly motivated to respond. There is, of course, no way to be certain whether those responding were more or less likely to be critical of the FDA. The response rate of 31% is quite good, considering the perceived potential for reprisal in this situation (one Medical Officer declined to provide his or her Division "for fear of retaliatory measures") and the difficulties in establishing Medical Officer addresses. In any event, the absolute numbers of Medical Officers expressing dissatisfaction with current FDA drug approval processes is extremely worrisome.
Even if one believes that non-response could bias the results, this criticism does not apply to questions seeking numbers of particular events (e.g., the number of drugs that have been approved despite the Medical Officer's opposition, those that were approved too fast, those that were approved only because post-marketing studies were required and those inappropriately shifted to the accelerated approval track). We did not ask the Medical Officers for the names of specific drugs, as this would have compromised their confidentiality. However, we believe that there is little, if any, overlap between the drugs mentioned. While "split reviews" in which more than one Medical Officer reviews an NDA do occur, our understanding from phone calls to FDA employees and our own experience over the years suggests that this is not common. With 53 Medical Officers responding from at least 11 of the FDA's 15 reviewing divisions, substantial overlap among the respondents between drugs is unlikely. For these questions, the limited number of responses more likely leads to an undercount of an already serious number of events. Similarly, the numbers of episodes in which the Medical Officer experienced inappropriate pressure are probably minimum estimates. In addition, the Medical Officers may not have been able to recall all events in the past three years and not all Medical Officers had been hired at the FDA for the full three years, resulting in further underestimates of the actual number of events.
See all figures: view graphs depicting the results of this survey.
Copyright © 2017 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.
You can support the fight for greater government and corporate accountability through a donation to either Public Citizen, Inc., or Public Citizen Foundation, Inc.
Public Citizen lobbies Congress
and federal agencies to advance Public Citizen's mission of advancing
government and corporate accountability. When you make a contribution to Public
Citizen, you become a member of Public Citizen, showing your support and entitling
you to benefits such as Public Citizen
News. Contributions to Public Citizen are not tax-deductible.
Public Citizen Foundation focuses on research, public education, and litigation in support of our mission. By law, the Foundation can engage in only very limited lobbying. Contributions to Public Citizen Foundation are tax-deductible.


text:
#3 Whitworth Falls On The Road
Walla Walla, Wash. - Whitworth's 20-game winning streak came to an end thanks to a 93-90 overtime loss at Whitman College on Tuesday night.
Wade Gebbers scored a career high 27 points for the Pirates, who fell to 20-2 overall and 12-1 in the NWC. The Missionaries improved to 15-7, 9-4 with the win.
Whitman led by as many as seven points midway through the first half after Jackson Clough's three-pointer gave the Missionaries a 23-16 lead. Whitworth rallied to tie the game 31-31 on a dunk by Taylor Farnsworth, but Whitman led 36-33 at halftime.
Whitworth came out of the locker rooms on a 14-4 run and took a 47-40 lead on Colton McCargar's lay up five minutes into the second half. The Pirates eventually stretched the lead to 53-44 on another McCargar basket with under 12 minutes to play.
Whitman began to climb back and was within 74-70 when Taylor Farnsworth was called for a foul and a technical with 29 seconds to play. Matt Mounier and Drew Raher each canned a pair of free throws to tie the game. McCargar came up big again for Whitworth, scoring the go-ahead basket with 10.9 second to go. But Mounier tied it with 4.7 left to tie the game 76-76 and force overtime.
Whitman outscored Whitworth 17-14 in the extra period. Mounier hit a three-pointer for an 84-81 Whitman lead sparked an 8-0 run from which the Pirates could not recover.


text:
Bo Shek
25th Anniversary Set Solo / Chewbacca
25th Anniversary Set Vader / Kenobi
EU Cloud Car w/ Pilot
EU Airspeeder w/ Pilot
SPAWN VI ( holding Sword and Malebolgias Head )
SPAWN VII ( Sitting on throne looking at skull )
VIOLATOR III ( holding human heaard )
SPAWN - Wings of Redemtion
Spawn Trade Paper Back #9 - #12
Flashback Vader
Flashback Leia
Potj R2-D2 Naboo Escape
Potj Darth Maul Final Duel
Potj Battle Droid Security ( 2x )
EP1 Darth Maul "Soft Goods" w/ Lightsaber
EP1 Obi Wan "Soft Goods" w/ Lightsaber
Ep1 Naboo Royal Security w/ Blaster and Helmet
Lot of vintage, but they are only good for customizing cause of loose limbs , no accessoires or yellowed plastic. Very few are still in good contition tough. Request list !!
Lot of SPAWN comic books from #40 to #81. and a few sublines like CURSE OF THE SPAWN, BLOODFEUD etc. Request list !!
Lot of WEST END GAMES STAR WARS RPG books and supplements. Request list !!


text:
The Armourlite AL1411 Professional Watch is a durable timepieces with a shatterproof crystal resting on a stainless steel case and rubber band for comfort. This professional watch is durable and versatile with date function and tritium illumination for clear visibility in the lowest of light conditions.
Free Shipping on All Domestic Orders
See international and additional shipping information here. Tax is only charged if shipping to California.
If, for any reason, your purchase wasn't exactly perfect, we honor return requests within 30 days from the original purchase date. To be eligible for a return, your item must be unused and in the same condition that you received it in. It must also be in the original packaging. Customer is responsible for return shipping costs. To initiate a return, please fill out the quick form at the bottom of our Returns Page.
Please note that special or custom-made orders are non-refundable, as well as any body care or hygienic products (you wouldn't want to purchase used body wash, right?).
For large adventure and furniture items, such as kayaks or paddle boards, a 20% restocking fee will be incurred as we do team lifts to repackage and put these heavy items back into storage.


text:
So, it's been a couple weeks since i've posted here. Feels like forever. My stay in Augusta is alright. I don't really connected with most of my peers here. Many of them have some growning up todo.
in other news, i've finished building my desktop. except i've found some weird linux errors. gentoo's live cd page faults into a system halt when i try building a reiser and ext3 partition.
when i install suse 9.1 personal edition, installation works perfectly. yet, when i try downloading debian's iso, after 10% of accomplished work, my computer hard locks.
i'm intrigued by this situation and i'm a little concerned.
in other news, the pdf filter for beagle is coming along well. just a couple more compile time bugs to squash and i should get to testing.
the delicious extension for epiphany has turned into a 'lets embed python' project. i'm a little annoyed right now b/c the ephy dudes are telling me that my testing modules aren't loading b/c of a linking error but, i've patched said error and they still aren't loading :( if anyone has written an epiphany 1.3 or greater extension/plugin, please contact me, i'd like to get the delicious one working before i start embedding a programming lanugage into the browser :P.
and with that, i go to sleep now. ubuntu looks promising.
New HTML Parser: The long-awaited libxml2 based HTML parser code is live. It needs further work but already handles most markup better than the original parser.
Keep up with the latest Advogato features by reading the Advogato status blog.
If you're a C programmer with some spare time, take a look at the mod_virgule project page and help us with one of the tasks on the ToDo list!


text:
Skip to Content
Great Public Schools for Every Student
More NEA Websites
Our Members
Back to: Tools And Ideas / Advice & Support / Works4Me / R / Reading Race
March 25, 2008
From Donna Dinizo-Ruhl, a teacher at Roosevelt School in South Plainfield, New Jersey
Send This article to:
Enter the e-mail address of the recipient. Multiple addresses need to be separated by commas (200 characters max).
Add your message (optional):
Enter your e-mail address (required):
NEA respects your privacy! Your e-mail address, and that of your recipient, will be used only in the case of transmission errors and to let the recipient know who sent the story. The information will not be used for any other purpose.
Your Email has been sent . Click here to return to the article.
Reported by:


text:
|Data Dictionary:
|Census 1930
you are here: choose a survey survey data set table details
Survey: Census 1930
|Data Source:
|Digitally transcribed by Inter-university Consortium for Political and Social Research. Edited, verified by Michael Haines. Compiled, edited and verified by Social Explorer.
Data set: Social Explorer Dataset (SE)
|T20B. Age (White Female Population) - Cumulative (More) [14]
Universe: White Female
Table Details
|Age (White Female Population) - Cumulative (More)
|Universe: White Female


text:
My Cart
You have no items in your shopping cart.
Currently Shopping by
Part no: RIG-55003
The ultimate gift for the 4x4 culture enthusiast.
Be the first to see new products and take advantage of special deals from Morris 4x4.
Mon - Fri 8am - 6pm EST
Sat 8am - 5pm EST
Join over 280,000 Jeep Enthusiasts Worldwide!
We've got some serious upgrades and we are excited to take you along for a ride.
Get $10 OFF your first order (over $75)


text:
Books and CDs Published by the NYG&B
Since its founding in 1870, the NYG&B has published numerous books and CDs which comprise unique record collections, research guides, family histories, and indexes to our periodicals. Many are available online to NYG&B members in our eLibrary. Some of our most recent publications are listed below. View a complete catalog of items that are available for purchase.
Recent Publications
An Armory of American Families of Dutch Descent
In Novmber 2010 the NYG&B published An Armory of American Families of Dutch Descent. This book gathers together for the first time all 36 articles on the heraldry of Dutch colonial families written by William J. Hoffman, the pre-eminent authority on the subject, and previously published in the New York Genealogical and Biographical Record along with his final article which appeared in the New England Historical and Genealogical Register. Edited by Francis J. Sypher, Jr., who has provided an introduction and an armorial index, this is an essential reference for anyone interested in the subject. The text is accompanied by numerous illustrations of arms, with detailed source references that provide both validation and opportunity for further research. The book was published on a subscription basis, and a small overrun was printed in order to accommodate anticipated interest in this definitive volume. A limited number remain for purchase in our store or by calling (212) 755-8532, ext. 208.
Kings County, New York, Administration Proceedings 1817-1856
When anyone dies without a will, Letters of Administration may be issued authorizing a relative or other individual to settle the estate under the supervision of the county Surrogate's Court. The Letters themselves contain minimal information of value, but for each of these estates the Court may have other papers relating to the estate proceedings, papers which may contain very useful genealogical data. Starting about 1830 they usually include a petition naming all the heirs-at-law and their places of residence. Noted genealogist B-Ann Moorhouse, assisted by Joseph Silinonte, abstracted all the administration proceedings files up to 1856. This book could be a genealogical goldmine for anyone researching families who lived in Brooklyn and the other Kings County towns during the first half of the 19th century. And since the court indexes only name the decedents, these abstracts may be only way you'll know the thousands of other names that appear in the files. Purchase the book in our store or read a description of the book, which is available in our members-only eLibrary.
Voices of the Irish Immigrant: Information Wanted Ads in The Truth Teller, New York City 1825-1844
In the two decades preceding the Famine there was already a considerable Irish immigration to North America, and given the limited communications of the time it was easy to lose track of relatives and friends who had crossed the Atlantic. "Information wanted" ads in newspapers were a means of locating these lost individuals. Diane Haberstroh and Laura DeGrazia have transcribed and indexed all the ads in surviving 1825-1844 issues of The Truth Teller, New York City's first Catholic newspaper. The ads mention names of several thousand immigrants living all over North America and, best of all for the genealogist, they also mention nearly 1,000 places of origin in Ireland. In addition to a personal name index the authors have created indexes to place names in the U.S., Ireland, and other countries, as well as to New York City streets (since relatives or fellow townsmen often settled in the same neighborhoods). Read a description of the book or purchase the book in our store.


text:
Manufacturer: Nike PCE Manufacturer: ELOGIC 3 Results
elago E7 ARMATURE In-Ear Noise-Reducing Earphones (Compatible iPhone 4, 1G/3GS; Control-Talk with Built In Microphone)
elago E7 ARMATURE In-Ear Earphones, Enjoy the deep bass and high definition sound quality that is pure elago, E7 Control - talk has a built in. feature for use with music phones and newer iPhone. The control talk cable has a call answer button and microphone so you can easily switch between listening to music asn talking on your iPhone.
Nike HJ080 Skylon Flight Metal 3-way Sport headphones
Skylon flight metal 3 way adjustable Sport headphones, have a radical new design aimed at athletes and Audiophiles. All metal, lightweight, 3-way adjustable for different size ears.
Nike HJ020 Flight Sport headphones
These Sport Headphones are specifically designed for runners and riders. The behind the head design with rear cable exit improves stability and comfort. They feature soft, sweat resistant earpieces. plus they sound great.


text:
Last edited by john fallon; 12-30-2012 at 11:47 PM.
"i guess the old saying 'those of us that think we know everything annoy those of you that does' " --bobbyb 9/13/06
"A Good Dog is a Good Dog"
I asked a TT rep once why the Flyway was a little cheaper. He said it was because of the targeted group of buyers (hunters) vs. dog trainers. Go figure.
Wayne Nutt
Go Nutts with dog training
HRCH Patton's Parker Co. Shadow "Shadow"
HRCH Clineline Hijacker "Jack"
HRCH Marks a Lot Midnight Hudson, SH "Hudson" RIP (5/26/01-6/18/15)
Castile Creeks Rawhide, MH "Rowdy"
Actually, on the G2 the 200 has tone, where as the flyway is inactive, except on the camo version. Not sure about the G3.
I use more nicks than burns in my training regimine ....... But if I need the continuous, the six levels of continuous stimulation variation of the flyway or 200, when coupled with years of duartion application, ostensibly gives one an infinate number of durations to work with ( read at least 12 more ) in the continuous mode.
Last edited by john fallon; 12-31-2012 at 12:07 PM.
"i guess the old saying 'those of us that think we know everything annoy those of you that does' " --bobbyb 9/13/06
"A Good Dog is a Good Dog"
pro 500 for sure
" I've got tone , firing" ... As Mike mentioned ,"I don't need 18 levels " I use a pro 100 , I rarely use a nick button ...I use the 2 and 3 levels with the different combination of low ,med ,high ...I would buy a Flyaway before a pro 200..and no way a 500....Steve S
Last edited by steve schreiner; 01-07-2013 at 08:54 PM.


text:
A while back, I blogged about using Illustrator for web design. Specifically, I wrote about using Illustrator and Dreamweaver together, lamenting about the lack of integration between the two applications. I've even had numerous discussions with the product managers for Dreamweaver over at Adobe about the topic.
To summarize, I questioned the apparent lack of support for moving art quickly from Illustrator into Dreamweaver via Smart Objects. The team kept asking me why I would care to bring vector art into Dreamweaver, and whatever would I do with it once it got there? My response was that I didn't want the vectors - I wanted Dreamweaver to generate pixels a la Smart Objects from the GoLive days.
Boy was I shortsighted. What was I thinking?
Each year, Adobe has their MAX conference. Unfortunately, due to a variety of reasons, I was not able to attend this year's conference in LA. One of the best sessions is something called "MAX SNEAKS" where Adobe shows tasty nuggets of technology from their labs. I'll mention that these aren't usually sneaks like features from the upcoming releases. Rather, the demonstrations are from Adobe's engineering scientists and generally cover things they are "messing with" that are often a while out, if at all. These are rarely polished demos and as I stated, the presenters aren't professional demo masters (of the likes of Greg Rewis or the incredible Jason Levine).
So take a look at this video that someone captured from this year's Adobe MAX Sneaks session -- a demo of technology showing integration between Illustrator and Dreamweaver. If it isn't clear in the video clip below what is happening, I'll spell it out for you: He starts by taking art drawn in Illustrator and copies it to the clipboard. Then he goes into Dreamweaver, selects a DIV and chooses a function called Smart Paste. Dreamweaver then pastes an FXG conversion of the Illustrator art directly into the page. If you aren't familiar with FXG, it's basically a better SVG (you can get more information on the open source FXG spec here). In other words, you draw in Illustrator, copy and paste into Dreamweaver (which converts it to code), and the art displays as vector art in a web browser. What's more, the engineer proceed to actually bind XML data to the chart.
As I mentioned, I think this is probably something that is way way off in the future, but it's still quite incredible. Maybe there's some hope for us all, after all :)
Thanks for the tasty treats Adobe! Can't wait to see the day when features like this come to life!


text:
'Why Things Fall' exhibition
Further Art
75 Bennett St. #M2
SCAD exhibitions presents "Why Things Fall," a group exhibition of new works featuring five M.F.A. students from the SCAD School of Fine Arts:
- Whitney Harrell
- Macey Ley
- Jeffry Loy
- Cassidy Russell
- Ziyi Zhang
The exhibition, curated by the students under the direction of printmaking professor Cynthia Lollis, refers to a shared theme of the work and offers insight into each artist's concepts. "Why Things Fall" is a statement about the condition of human nature in both its raw and domesticated forms. Rules of gravity and those of society play primary roles in each of the works on display.
Reception: Friday, Jan. 24, 6-9 p.m.
Gallery hours: Saturday, Jan. 25, 10 a.m. to 3 p.m.
The exhibition and reception are free and open to the public.


text:
Did you feel it?
Why It Matters
Did you just feel an earthquake? Have you ever experienced an earthquake?
When you do experience a quake, pay close attention to what time it is, what items are shaking around you, and what type of structure you are in. Go to the United States Geological Survey's website and log your data:
As more people enter their data, you can revisit the site to see how other people's experiences match up with yours!
Explore More
- Here is some history on the USGS "Did you feel it?" program: http://pubs.usgs.gov/fs/2005/3016/pdf/FS-2005-3016.pdf How has this citizen driven data helped U.S.G.S. geologists?
- Using the Community Internet Intensity map in the USGS pdf, where have the highest intensities been reported by citizens across the United States? How does this compare with the seismic hazards map shown on the following page?
- Looking at the Intensity level chart and the two example intensity maps of southern California, what types of observations do you think locals experienced during the magnitude 7.1 earthquake? How did their experience differ in the 4.4 magnitude quake?
Resources Cited
United States Geological Survey. http://earthquake.usgs.gov/earthquakes/dyfi/